Kuvan (sapropterin dihydrochloride)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) June 2016 ADVERSE REACTIONS Clincial Trials Experiences PKU Clinical Studies In Study 7, 27 pediatric patients with PKU aged...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts